Predict your next investment

Corporation
onxeo.com

See what CB Insights has to offer

Partners & Customers

7

About Onxeo

Onxeo (Paris: ONXEO) is a developer of orphan oncology drugs. The company is focused on developing therapeutics for rare cancers, one of the fastest growing markets in the healthcare industry with high, unmet medical needs. Onxeo's comprehensive portfolio features a broad orphan oncology pipeline, with three independent programs in advanced clinical development, including Onxeo's first approved orphan oncology drug, Beleodaq.

Onxeo Headquarter Location

49 boulevard du General Martial Valin

Paris, 75015,

France

+33 (0)1 45 58 76 00

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Onxeo

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Onxeo in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest Onxeo News

Q&A: EASL recommends Tecentriq plus Avastin as standard of care for HCC

Sep 15, 2021

Disclosures: Sangro reports receiving consulting fees from Adaptimmune, AstraZeneca, Bayer, Bristol Myers Squibb, BTG, Eisai, Exelixis, Eli-Lilly, IPSEN, Merck, Onxeo, Roche, Sirtex; receives lecture fees from AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Eli-Lilly, Incyte, IPSEN, Roche, Sirtex and receives institutional research grants from Bristol Myers Squibb and Sirtex. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Recently the European Association for the Study of the Liver updated its clinical practice guidelines for management of hepatocellular carcinoma. Healio Gastroenterology spoke with Bruno Sangro, MD, director of the liver unit at Clínica Universidad de Navarra, and professor of internal medicine at the University of Navarra School of Medicine, in Pamplona, about EASL’s latest update to the recommendations for systemic therapy of HCC . Bruno Sangro Healio: Why did EASL decide to update the recommendations for systemic therapy of HCC? Sangro: The recommendations that were in the last version of the guidelines were introduced before the IMbrave-150 clinical trial had reported results and so the recommendation was sorafenib [Nexavar; Bayer] or lenvatinib [Lenvima; Eisai] as first-line therapies, followed by regorafenib [Stivarga; Bayer], cabozantinib [Cabometyx/Cometriq; Exelixis] or ramucirumab [Cyramza; Eli Lilly] as per the corresponding clinical trial data. The introduction of atezolizumab [Tecentriq; Genentech] plus bevacizumab [Avastin; Genentech] made us understand that there was an urgent need for recommendation in this systemic therapy field. This has changed entirely the way we should do systemic therapy in HCC patients. Healio: Can you discuss EASL’s new recommendations for systemic treatment of HCC? Sangro: The most important advance has been the introduction of atezolizumab plus bevacizumab as the standard of care in most countries, once the regulatory agencies have approved this based on the results of the IMbrave-150 trial. This is the most important advance that has, in turn, introduced several changes in the way we treat patients with systemic therapy. Up to now, we had sorafenib or lenvatinib as the standard of care, and other tyrosine kinase inhibitors and the VEGFR2 inhibitor ramucirumab as second line therapies, with certain limitations such as alpha-fetoprotein levels for ramucirumab or tolerability to sorafenib for regorafenib. What the introduction of atezolizumab plus bevacizumab as the recommended first-line therapy means is that there is virtually no experience regarding the efficacy of any other treatment, a second-line therapy, after atezolizumab plus bevacizumab. We recommend that decisions in this second-line setting should be based on different factors. First, availability, because not all drugs are equally accessible in different countries. Second, the toxicity profile of each agent and the patient characteristics making some toxicity profiles more or less appealing for a given patient. And third, to consider that there is no hierarchy. There is no reason to understand that lenvatinib, or even cabozantinib, should not be considered at the same level as sorafenib. The concept of sorafenib prior to any second-line drug should not be maintained once atezolizumab plus bevacizumab is the first line. These are the two main statements in the guidelines. Atezolizumab plus bevacizumab is the recommended first-line systemic therapy. Second-line systemic therapy would be a TKI. Then it is important to understand the population that should be treated. It includes all patients with metastases, or vascular invasion, but also those patients with liver disease in whom the burden of disease is too large to be fit for therapies like chemoembolization or radioembolization. In addition, the specific contraindications for either atezolizumab or bevacizumab should be considered when making the decision to treat a patient with atezolizumab plus bevacizumab. This position paper tries to provide guidance for physicians who deal with HCC, telling them what the currently available scientific evidence is and how this supports the decision to start, the option to choose, and the different ways that one can make the best out of the therapy by identifying adverse events and treating them correctly or addressing the needs for special population. We've also covered the evidence supporting treatment in special populations, from patients with liver transplantation to patients in hemodialysis, with viral co-infections, etc., and guidance for those specific indications for physicians treating patients with HCC. Healio: Can you discuss the difference between first- and second-line therapies in HCC? Sangro: First-line therapy means the therapy that you should consider in any patient who is a candidate for systemic therapy. It’s atezolizumab and bevacizumab based on the reported overall survival benefit compared to sorafenib. Not sorafenib but not lenvatinib either because lenvatinib was only non-inferior to sorafenib. Therefore, sorafenib or lenvatinib should only be considered the first option when there is a contraindication to any of the components of the combination. You need to have a contraindication to any of the drugs to recommend a different therapy. Healio: Will there be a trial or trials that you know of assessing the role of systemic therapies in stages beyond the advanced stage HCC? Sangro: There are different phase 3 trials running in the intermediate stage, testing the combination of transarterial chemoembolization with immunotherapy based on PD-1, PD-L1 inhibitors, plus/minus bevacizumab. In the earliest stages, there are also trials testing immunotherapy alone or in combination with bevacizumab as adjuvant therapy after successful resection or percutaneous ablation, but we still don't have any information coming from those trials, those are ongoing trials.

Onxeo Acquisitions

3 Acquisitions

Onxeo acquired 3 companies. Their latest acquisition was DNA Therapeutics on February 29, 2016.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

2/29/2016

Seed VC

$991

$1.1M

Acquired

2

5/22/2014

Subscribe to see more

$99M

Subscribe to see more

10

5/22/2014

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/29/2016

5/22/2014

5/22/2014

Investment Stage

Seed VC

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

Total Funding

$1.1M

$99M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Sources

2

10

10

Onxeo Partners & Customers

7 Partners and customers

Onxeo has 7 strategic partners and customers. Onxeo recently partnered with Acrotech Biopharma on April 4, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

4/16/2020

Licensee

Acrotech Biopharma

United States

Onxeo S.A.’s $6.6 Million Agreement with Acrotech Biopharma LLC

Onxeo S.A. , a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response , in particular against rare or resistant cancers , announced that it has entered into agreements with Acrotech , a wholly-owned subsidiary of Aurobindo Pharma , which extend Acrotech 's rights to belinostat , to all territories not previously covered under Onxeo S.A. 's prior agreement with Acrotech as well as transfer certain IP and know-how related to belinostat in all its forms .

1

1/29/2020

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

4/24/2017

Licensee

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

1/31/2017

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

7/27/2016

Licensee

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

4/16/2020

1/29/2020

4/24/2017

1/31/2017

7/27/2016

Type

Licensee

Partner

Licensee

Partner

Licensee

Business Partner

Acrotech Biopharma

Country

United States

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

News Snippet

Onxeo S.A.’s $6.6 Million Agreement with Acrotech Biopharma LLC

Onxeo S.A. , a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response , in particular against rare or resistant cancers , announced that it has entered into agreements with Acrotech , a wholly-owned subsidiary of Aurobindo Pharma , which extend Acrotech 's rights to belinostat , to all territories not previously covered under Onxeo S.A. 's prior agreement with Acrotech as well as transfer certain IP and know-how related to belinostat in all its forms .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Onxeo Team

2 Team Members

Onxeo has 2 team members, including former Founder, Chief Operating Officer, Gilles Avenard.

Name

Work History

Title

Status

Gilles Avenard

Founder, Chief Operating Officer

Former

Piers J Morgan

Chief Financial Officer

Former

Name

Gilles Avenard

Piers J Morgan

Work History

Title

Founder, Chief Operating Officer

Chief Financial Officer

Status

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.